NCT Number: NCT00231062
Clinical Evaluation to Confirm Safety and Efficacy of Sinuplasty in the Paranasal Sinuses (CLEAR)
A multi-center, non-randomized, prospective post-market evaluation of sinuplasty in paranasal sinuses.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
About this study
Sinusitis is a common healthcare problem that significantly reduces quality of life for people around the world. Patients suffer from headache, facial discomfort, nasal congestion, nasal drainage, loss of the sense of smell and malaise. Sinusitis is responsible for major healthcare expenditure and loss of workplace productivity.
The rationale of this study is to collect data on the effectiveness and safety of balloon dilation of the Frontal, Maxillary and Sphenoid sinuses by treating patients and observing them for a six month period of time following the procedure. Six month follow-up data is important to demonstrate the effectiveness of balloon catheter dilation.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Age 18 years and greater
- Both male and female patients eligible
- Diagnosis of chronic sinusitis that is not responsive to medical management
- Planned endoscopic sinus surgery (recommended by PI, consented to by patient)
Exclusion criteria
- Extensive sinonasal polyps
- Extensive previous sinonasal surgery
- Extensive sinonasal osteoneogenesis
- Cystic fibrosis
- Sampter's Triad (Aspirin sensitivity, Asthma, Sinonasal polyposis)
- Sinonasal tumors or obstructive lesions
- History of facial trauma that distorts sinus anatomy and precludes access to the sinus ostium
- Ciliary dysfunction
- Pregnant females
Treatment and study plan
Primary outcomes
-
Number of Sinuses With Patency of Sinus Ostium After Sinuplasty
Time frame: 24 weeks
Patency of sinus ostium after sinuplasty will be determined by nasal endoscopic examination. The investigator will make a clinical judgment as to whether or not this has been achieved.
-
Number of Participants With Adverse Events Following Sinuplasty Procedure
Time frame: 24 weeks
Adverse event rate at 24 weeks: comprised of all observed peri-operative adverse events which were recorded on dedicated CRFs and any observed or patient-reported post-operative adverse events will be similarly recorded (through 24 week follow-up).
Secondary outcomes
-
Number of Participants Experiencing Relief of Sinus Symptoms
Time frame: Week 24
To gain general insight into the ability of balloon catheter sinus ostial dilation to relieve sinus symptoms, scores from the pre-operative SNOT-20 evaluations were compared to scores from the post-procedure SNOT-20 evaluations at 24 weeks following the procedure. The number of participants who showed aggregate symptom relief are recorded here as having been successfully treated.
Sponsors and collaborators
Lead sponsor
Integra LifeSciences Corporation
Industry
Collaborators
- Acclarent
Registry information
Important dates
- Study start
- 2005
- Primary completion
- 2006
- Study completion
- 2006
- First posted
- Oct 4, 2005
- Registry last updated
- Aug 6, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Dupilumab in CRSsNP
NCT04678856
Chronic Rhinosinusitis Without Nasal Polyps, Chronic Sinusitis
Roseville, California, United States
View Trial DetailsEfficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
NCT04362501
Bronchial Diseases, Bronchiolitis
Baltimore, Maryland, United States
View Trial DetailsNitric Oxide Releasing Sinus Irrigation (NOSi) to Treat Recalcitrant Chronic Rhinosinusitis (RCRS)
NCT04163978
Chronic Sinusitis, Infections
Vancouver, British Columbia, Canada
View Trial DetailsXylitol Versus Saline in Chronic Sinusitis
NCT00924404
Chronic Sinusitis, Infections
Iowa City, Iowa, United States
View Trial Details